Abstract
Vascular endothelial growth factor receptor 3 (Vegfr3) has been widely used as a marker for lymphatic and vascular endothelial cells during mouse embryonic development and in adult mouse, making it valuable for studying angiogenesis and lymphangiogenesis under normal and pathological conditions. Here, we report the generation of a novel transgenic (Tg) mouse that expresses a membrane-localized fluorescent reporter protein, Gap43-Venus, under the control of the Vegfr3 regulatory sequence. Vegfr3-Gap43-Venus BAC Tg recapitulated endogenous Vegfr3 expression in vascular and lymphatic endothelial cells during embryonic development and tumor development. Thus, this Tg mouse line contributes a valuable model to study angiogenesis and lymphangiogenesis in physiological and pathological contexts.
Introduction
The vascular endothelial growth factors (VEGFs) play as critical regulators of vascular development among mammalian species [1]. The VEGF family consists of six secreted proteins (VEGF-A, B, C, D, E and placental growth factor), which have different binding affinities for three tyrosine kinase receptors; VEGFR1 (Fms-like tyrosine kinase 1; Flt1), VEGFR2 (Fetal liver kinase 1; Flk1), VEGFR3 (Fms-like tyrosine kinase 4; Flt4)[1,2]. VEGF family members also bind to non-tyrosine kinase receptors, Neuropilin1 and 2, which are considered to function as co-receptors for the VEGFRs. VEGF-A and VEGF-B and placental growth factor bind to VEGFR1, VEGF-A and VEGF-C to VEGFR2, and VEGF-C and VEGF-D to VEGFR3. VEGF-C binds to VEGFR2/VEGFR3 heterodimer and transduces signals through Akt, whereas VEGFR3/VEGFR3 homodimer transduces signals through ERK [3].
In adult tissues, VEGFR1 and VEGR2 are most strongly expressed and play a crucial role in vascular endothelial cells [4]. In contrast, VEGFR3 expression initially occurs in vascular endothelial cells, and then is maintained both in vascular and lymphatic endothelial cells, later becoming largely restricted to lymphatic endothelial cells [5]. However, VEGFR3 is induced again at a high level in vascular endothelial cells in adulthood during physiological and pathological angiogenesis [6], and blocking VEGFR3 with antibodies results in decreased angiogenesis during postnatal retinal development [7]. Other researchers have reported that Notch-dependent VEGFR3 up-regulation allows angiogenesis without VEGF/Flk1 signaling. VEGFR3 is also expressed in non-endothelial cells such as neural cells, macrophages and osteoblasts [8,9]. Thomas and coworkers showed that VEGFR3 is expressed in neural stem cells and its function is required for neurogenesis.
For better understanding the cellular and molecular mechanism of angiogenesis, we created animal models useful for visualization and live imaging of vascular endothelial cells expressing VEGFR1 or VEGFR2 [10,11]. For example, we generated Vegfr2-GFP BAC transgenic mice to monitor Vegfr2 gene expression during development [10,12]. Although Vegfr1 and Vegfr2 are expressed in most endothelial cells during development, the expression levels are different in specific endothelial cells, such as tip and stalk cells in the developing retina, and their relative expression levels correlate with the position of the endothelial cells. In double transgenic mice expressing both Vegfr2-GFP and Vegfr1-tDsRed genes, significantly different expressions between Vegfr2 and Vegfr1 were observed in E9.5 embryos [11]. The Vegfr2-GFP :: Vegfr1-tDsRed double transgenic mice have been used by a number of laboratories [13].
Here, we report the generation of a novel fluorescent reporter mouse line expressing a membrane bound form of Venus, a bright fluorescent protein [14], under the control of the Vegfr3 BAC (bacterial artificial chromosome) transgene to visualize VEGFR3 expression during embryonic development and in adulthood. Our results show the recapitulation of endogenous VEGFR3 expression governed by Vegfr3-Gap43-Venus BAC Tg in the vascular endothelial and lymphatic endothelial cells. Our result also shows that the Tg mouse is useful for illuminating the cell shape of endothelial cells owing to the advantage of membrane-tagged Venus. This will serve as a valuable tool for marking VEGFR3-expressing cells during development and in adulthood under normal and pathological conditions.
Material and methods
Constructing the Vegfr3-Gap43-Venus BAC Tg transgene
The BAC clone (RP23-210C22) encompassing the mouse Vegfr3 gene was purchased from Invitrogen (Carlsbad, CA, USA). A DNA fragment encoding membrane localization signal of mouse Gap43 (5’-ATGCTGTGCTGCATGCGAAGAACCAAACAGGTTGAAAAGAATGATGAGGACCAAAAGATC-3’) was ligated to a Venus-bGH polyA cassette and the resultant DNA was further ligated to an FRT PGK-gb2 neo expression cassette that comprises a prokaryotic promoter and neomycin-resistance gene flanked by FRT sequences (Gene Bridges, Heidelberg, Germany). Homology arms for the second exon of Vegfr3 were amplified by two pairs of primers as follows: 5’arm-1: 5’-ATACTCGAGACGCGTGGCCTTGACCAGAGCAAGGAACAG-3’, 5’arm-2: 5’-ATAGAAGACCGGGGCCGGGGTTCTCCTC-3’, 3’arm-1: 5’-ATAGCGGCCGCGTATCCTGGCTCCTCCCCACCTG-3’, and 3’arm-2: 5’-ATAGGCGCGCCAGATCCACTCCCTGAGCCCTTGAC-3’. Afterwards, the arms were ligated to both ends of the reporter cassette. The resulting donor vector and RED/ET expression plasmid (Gene Bridges) were introduced into Escherichia coli. The recombinants were identified by PCR analysis. The neo cassette was excised by transient expression of FLPe (Gene Bridges).
Generating Tg mice
Recombinant BAC DNAs for Vegfr3 were purified with a NucleobondXtra BAC Kits (Macherey-Nagel, Düren, Germany) and then linearized by Pl-SceI digestion. Pronuclear injection was performed in fertilized eggs isolated from C57B6/J females (SLC Inc., Shizuoka, Japan). Tg mice were confirmed by PCR genotyping with the following primer sequences: GFP-S2, 5’-TTCAAGGACGACGGCAACTACAAGAC-3’ and GFP-AS2: 5’-GCTTCTCGTTGGGGTCTTTGCTCAG-3’. The Tg mice were maintained on ICR or C57B6/J genetic background. Vegfr2-GFP BAC Tg mice[10], Vegfr1-tDsRed BAC Tg mice[11], Vegfr2+/GFP knock-in mice[15] were described as previously.
The experimental procedures were approved by the ethics committee for Animal Experimentation of Shiga University of Medical Sciences (Approval number: 2016-2-8) (Committee member is Akira Andoh, Jun Udagawa, Masatsugu Ema, Kazumasa Ogasawara, Shinichiro Nakamura, Kazuhiko Nozaki, Seiji Hitoshi, Kihachiro Horiike, Yoshihito Muroji, Shigehiro Morikawa). Masatsugu Ema was not involved in the judgement. Implantation of LLC tumor cells was performed under isoflurane anesthesia.
Immunohistochemical analysis
Embryos were then dissected, and fixed in 4% paraformaldehyde for 3 h at 4°C as described previously [16]. For whole mount immunohistochemistry, after washing twice in PBS, embryos were permeabilized in 0.5% TritonX-100 (Sigma-Aldrich, St. Louis, MO, USA) in PBS for 30 min at 4°C. Permeabilized embryos were then blocked in blocking solution containing 10% donkey serum (Immuno Bioscience, Mukilteo, WA, USA), 0.2% bovine serum albumin (Sigma-Aldrich) and 0.01% PBT (0.01% Tween20 in PBS, Nacalai Tesque, Inc., Kyoto, Japan) for 1 h at 4°C, followed by incubation overnight at 4°C. After three washes with 0.2% PBT, embryos were incubated with secondary antibodies, listed in S1 Table, for 3 h at 4°C. Embryos were then washed three times with 0.2% PBT and incubated with anti-GFP Alexa-Fluor488 conjugate (1:200; Cat #A21311, Life Technologies, Inc. Carlsbad, California) for 1 h at RT. Nuclei were stained with Hoechst33342 (10 μg/ml; Cat #H3570, Molecular Probes Inc.) for 20 min at 4°C. The first and second antibodies are listed in S1 Table.
For cryosections, embryos, adult back skin and tumors were mounted in OCT (Surgipath FSC 22 Blue Frozen section compound; Leica, Wetzlar, Germany) as described previously. Tissue blocks were sectioned using a cryostat (CM1860 UV; Leica). The sections were processed as described previously [16] and mounted by PermaFluor (Thermo Fisher Scientific, Waltham, Mass). For staining of cortex at E14.5 and E17.5, 100μm coronal sections were stained by the procedure for whole mount embryos.
Confocal microscopy
Images of embryos were captured by Leica MZ FLIII with a GFP LP filter (Leica Microsystems, Wetzlar, Germany). Confocal images were acquired on a Leica TCS-SP8 (Leica). Embryos were mounted in PBS on glass-bottom dishes (IWAKI, Tokyo, Japan). Fluorescence was excited with a 405-nm UV laser for Hoechst 33342, a 638-nm laser for Cy5 or Alexa Fluor 633, a 552-nm laser for Cy3, and a 488-nm laser for Alexa Fluor 488. The hybrid detector HyD (Leica) was used for signal detection. 3D reconstruction was performed by 3D viewer software (Leica) from z-stack images every 5 μm.
Quantitative colocalization analysis
Images acquired from confocal microscopic analysis were processed by NIH ImageJ FIJI version 2.0.0-rc-65/1.5/w software [17]. In brief, RGB color images were converted into grey scale images and Pearson’s R-values (above thresholds) were calculated and presented as a 2D intensity histogram.
Western blotting
E9.5 embryos dissected from Vegfr3-Gap43-Venus BAC Tg mice were treated with 0.25% trypsin (Thermo Fisher Scientific) for 5 min at 37°C and Venus-positive cells were sorted by a FACSAria Fusion instrument (BD Biosciences, Franklin Lakes, NJ, USA). The sorted Venus-positive cells were suspended in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA (pH 8.0), 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) to obtain the whole cell extract. Ten micrograms of a total protein sample was electrophoresed by a 10% SDS-PAGE gel and transferred to a PVDF membrane (Millipore, Burlington, MA, USA). The membrane was treated with blocking reagent (TBS, 0.1% Tween, 5% skim milk (Difco, Franklin Lakes, NJ, USA)), incubated with anti-VEGFR3 and subsequently with secondary antibodies conjugated with horseradish peroxidase (HRP). The signal was detected by Chemi-Lumi One L (Nacalai Tesque).
Flow-cytometry analysis with the pERK antibody
Venus-positive and–negative cells from Vegfr3-Gap43-Venus BAC Tg embryos at E9.5 and were cultured in the presence of 5 μM MEK inhibitor (PD0325901; Wako, Osaka, Japan) for 30 min in a CO2 incubator. The cells were fixed and permeabilized with Perm Buffer III (BD Biosciences) for 30 min at 4°C and treated with the pERK antibody. FACS analysis was performed with a FACS Calibur instrument (BD Biosciences).
Tumor implantation
Lewis lung carcinoma (LLC) cells were cultured in DMEM (BD Biosciences) containing 10% fetal bovine serum (Sigma). After the LLC cells were trypsinized, 5×105 cells were suspended in D-PBS(-) (Nacalai Tesque, Kyoto, Japan) and implanted into the back of a mouse. To examine tumor angiogenesis, we implanted LLC cells in 12-week-old WT and Vegfr3-Gap43-Venus BAC Tg mice.
Results
Generating Vegfr3-Gap43-Venus BAC Tg mice
To generate transgenic (Tg) mice recapitulating endogenous membranous VEGFR3 expression, we used an enhanced yellow fluorescence protein Venus [14] with a short plasma membrane localization signal from mouse Gap43. We ligated the Gap43 tagged-Venus reporter cassette to the second exon of Vegfr3 in the BAC clone (Fig 1A), and generated four lines of Vegfr3-Gap43-Venus BAC Tg mice. To check Venus expression, we dissected embryos at E7.5 and E8.5 from four Tg lines and found strong Venus expression in the extraembryonic mesoderm at E7.5 and endothelial cells at E8.5 in all Tg lines (Fig 1B and 1C, data not shown), indicating that the Vegfr3-Gap43-Venus BAC Tg construct can efficiently direct expression in endothelial cells. Two independent Vegfr3-Gap43-Venus BAC Tg embryos (line# 3–2 and 7) at E9.5 showed clear Venus expression in the vascular system and these two lines were used throughout this study (Fig 1E and 1F).
Venus expression in Vegfr3-Gap43-Venus BAC Tg embryos
Given the observation that endogenous VEGFR3 expression was recapitulated in the vascular system of Vegfr3-Gap43-Venus Tg embryos, we examined the detailed expression of Venus during embryonic development. Embryos collected at E9.5 were stained with antibodies for Venus, VEGFR3, and a vascular endothelial marker, VE-cadherin (Fig 2). Venus, VEGFR3 and VE-cadherin expressions were well-overlapped in the endothelial cells of the head region and intersomitic vessels (Fig 2).
Because we used Venus with the membrane-localization signal of Gap43, we examined the cellular localization of Venus and found that the Gap43-Venus fluorescence pattern was very similar to that of endogenous VEGFR3 and PECAM1, which illuminate the tubular structure of blood vessels and cell shape of endothelial cells (Fig 3). In contrast, GFP without a membrane localization signal directed by Vegfr2 was expressed in PECAM1-positive endothelial cells, but each GFP signal was intensely localized in the cytoplasm and was apparently different from those of VEGFR3 and PECAM1 (Fig 3). Thus, our Vegfr3-Gap43-Venus BAC Tg mouse is very useful for visualizing the cell shape and tubular structure of endothelial cells.
To confirm the overlapped pattern of Venus and VEGFR3 in more detail, cryosections were prepared and subjected to immunohistochemistry (Fig 3). Venus expression was well-overlapped with that of endogenous VEGFR3 and PECAM1 at dorsal aorta and cardinal vein. Collectively, these results demonstrated that Vegfr3-Gap43-Venus BAC Tg is capable of recapitulating endogenous Vegfr3 expression in developing vascular endothelial cells.
Because VEGFR3 expression has been reported to be downregulated in vascular endothelial cells at the dorsal aorta, which restricts to lymphatic endothelial cells in the skin around E14.5 [5], we examined Venus expression in the back skin of E14.5 embryos and found that Venus expression was overlapped with that of endogenous VEGFR3 and Lyve1-positive lymphatic endothelial cells (Fig 4A). Prox1 -positive lymphatic endothelial cells that were integrated into tubular structures were positive for Venus (Fig 4B), indicating that Venus expression driven by Vegfr3-Gap43-Venus BAC recapitulates the endogenous expression of Vegfr3 in lymphatic endothelial cells. We also examined Venus expression in the brain of Vegfr3-Gap43-Venus BAC Tg mice at E14.5 and E17.5 (Fig 4C, S1 Fig), and found that Venus was well-overlapped with that of endogenous VEGFR3 and was expressed in IsolectinB4-stained vascular endothelial cells (Fig 4C, S1 Fig), indicating that the timing of downregulation of VEGFR3 in vascular endothelial cells differs from organ to organ (Fig 4).
Venus expression in Vegfr3-Gap43-Venus BAC Tg adult mice and in a tumor model
In adult mice, Vegfr3 expression is restricted to lymphatic endothelial cells and is not detectable in most, if not all, vascular endothelial cells. However, when vascular endothelial cells invade a tumor, VEGFR3 is highly upregulated in the vascular endothelial cells and is required for tumor angiogenesis [7]. Consistent with this report, in the normal back skin of adult mice, we found that Venus was expressed predominantly in Lyve1-positive lymphatic endothelial cells, but not PECAM1-positive vascular endothelial cells (Fig 5A). However, when Lewis lung carcinoma (LLC) cells were implanted into the back skin of Vegfr3-Gap43-Venus BAC Tg mice, Venus was markedly upregulated in the PECAM1-positive endothelial cells in the tumor (Fig 5B). Additionally, we found Venus-positive and PECAM1-negative cells with a round morphology (Fig 5B). Previous reports showed that macrophages that infiltrate tumors express VEGFR3 and are critical for tumor progression [8,18]. Thus, we performed immunohistochemistry with a marker for macrophage, F4/80 and found that the substantial number of Venus-positive cells with a round morphology express F4/80, suggesting that they are macrophages infiltrating into the tumor (Fig 5B). Therefore, Vegfr3-Gap43-Venus BAC Tg is capable of recapitulating endogenous Vegfr3 expression in adult mice and tumor model.
Dual imaging of VEGFR3 and VEGFR1
Previously, we created animal models for imaging of Vegfr1 and Vegfr2 expression and found substantial differences between Vegfr1 and Vegfr2 expression patterns in embryos at 9.5 dpc; Vegfr1 expression was more prominent in large blood vessels such as the dorsal aorta, while Vegfr2 expression was more prominent in microcapillaries [11]. In order to investigate whether our Vegfr3-Gap43-Venus BAC Tg mice could be used for simultaneous imaging of Vegf Receptors, we tried to detect Vegfr3 and Vegfr1 expressions simultaneously. We detected clear signals of Vegfr3-Venus in Prox1-positive lymphatic endothelial cells and Vegfr1-tDsRed in vascular endothelial cells of the back skin of Vegfr3-Gap43-Venus BAC Tg :: Vegfr1-tDsRed BAC Tg embryos at E14.5 (Fig 6A, S2 Fig).
Cardiac lymphatic system arises from heterogeneous origins [19]. Thus, we investigated the expression of Venus, tDsRed and Prox1 in the heart of the Tg mouse at E14.5 (Fig 6B, S2 Fig) and found co-expression of Venus and Prox1 in the heart at E14.5. Compiled images along z-stack clearly illuminate 3D-structures of lymphatic system and coronary vasculature (S1 Movie). In the brain at E14.5, we found most, if not all, vascular endothelial cells expressed Vegfr3, while Vegfr1 was expressed more strongly in larger vessels (Fig 6C, S2 Fig).
Taken together, the Vegfr3-Gap43-Venus BAC Tg mice established in this study is useful for studying angiogenesis and lymphangiogenesis in combination with Vegfr1-tDsRed BAC Tg mice.
Quantitative colocalization analysis
We have shown that our Vegfr3-Gap43-Venus BAC Tg mice recapitulate endogenous VEGFR3 expression by presenting Venus and VEGFR3 expression at various developmental stages (Figs 2–6, S1 and S2 Figs). To quantitatively examine the colocalization of Venus and VEGFR3, three independent immunostaining experiments for Venus and VEGFR3 expression were performed on E9.5, E14.5 embryos and adult skin (Fig 7), and the image data were analyzed by the ImageJ FIJI software. The analysis clearly demonstrated that the Venus reporter expression is significantly associated with the pattern of endogenous VEGFR3 (Fig 7), thus strengthening the usefulness of Vegfr3-Gap43-Venus BAC Tg reporter mice.
Potential use for studying the mechanism of VEGFR3 activity
Although the main purpose of this study was to create a useful Vegfr3 reporter mouse to enable researchers to study angiogenesis and lymphangiogenesis, we have attempted to show that Vegfr3-Gap43-Venus BAC Tg mice are also valuable for studying the mechanism of VEGFR3 activity during embryonic development by molecular and biochemical analysis (Fig 8). We have sorted Venus-positive endothelial cells from E9.5 Vegfr3-Gap43-Venus BAC Tg embryos (Fig 8A) and confirmed that VEGFR3 is enriched in Venus-positive endothelial cells by western blot analysis (Fig 8B). We then showed by flow-cytometry analysis that the percentage of pERK-positive cells in Venus-positive endothelial cells is significantly reduced by MEK inhibitor treatment (Fig 8C and 8D). Thus, we have shown that our Vegfr3-Gap43-Venus BAC Tg mice can be used for studying the mechanism of VEGFR3 activity (Fig 8).
Discussion
In this study, we demonstrated that Vegfr3-Gap43-Venus BAC Tg can recapitulate endogenous VEGFR3 expression in vascular endothelial cells and lymphatic endothelial cells during embryonic development and in adulthood. By using Venus with a plasma membrane localization signal, the clear tubular structure of vessels and the cell shape of endothelial cells could be visualized in Vegfr3-Gap43-Venus BAC Tg mice. Overall, Venus expression was much stronger and clearer with less background signal than that of antibody staining against VEGFR3. In tumor tissue, it is generally difficult to detect endogenous gene expression, including VEGFR3, by immunohistochemistry. In contrast, Vegfr3-Venus is bright and detectable easily as described in our study, and will thus be very useful for studying angiogenesis during tumorigenesis.
Simultaneous imaging of vascular endothelial cells and lymphatic endothelial cells is useful for studying angiogenesis and lymphangiogenesis. Azar and coworker established Prox1-GFP :: Flt1-tDsRed Tg mice for simultaneous imaging of angiogenesis and lymphangiogenesis [20]. We demonstrated that the Vegfr3-Gap43-Venus :: Vegfr1-tDsRed BAC Tg mice established in this study can be used to visualize developing vascular endothelial cells in the brain, lymphatic endothelial cells in the heart, and in other areas. Furthermore, in contrast with Prox1-GFP, our Tg utilizes a Venus with Gap43 membrane localization signal and has an advantage to illuminate cell shape of endothelial cells such as tip cells.
VEGF-C binds to VEGFR2/VEGFR3 heterodimer and activates Akt signaling, whereas VEGFR3/VEGFR3 homodimer activates ERK signaling [3]. It is important to distinguish cells expressing VEGFR2 alone, VEGFR3 alone or VEGFR2/VEGFR3. For that purpose, we established Vegfr3-Gap43-Venus :: Vegfr2+/GFP knock-in mice and tried to distinguish Venus and GFP fluorescence. However, close excitation and emission wavelengths between Venus and GFP, and the strong fluorescent intensity of Vegfr2-GFP over Vegfr3-Venus hampered dual detection of the Vegfr2-GFP and Vegfr3-Venus signal (C. W., M. E. unpublished observation). In the future, red fluorescent protein in Vegfr3 BAC Tg or cyan fluorescent protein in Vegfr2 BAC Tg mice will be needed for dual imaging of VEGFR2 and VEGFR3.
Previous studies have shown that Vegfr3 is expressed in vascular endothelial and lymphatic endothelial cells [5], neural stem cells [21], macrophages and osteoblasts [8,9], and it is important for vascular development [21], lymphangiogenesis [6] and neural stem cells [9]. Therefore, it is very important to understand exactly where and at what level it is expressed. Taken together, the Vegfr3-Gap43-Venus BAC Tg mice established in our study may be used to investigate novel functions of Vegfr3 as well as to study tumor angiogenesis.
Supporting information
Acknowledgments
We would like to thank Ms. Yuko Suzuki for preparing the BAC Tg DNA.
Data Availability
All relevant data are within the paper and its Supporting Information files.
Funding Statement
This research was supported by the Japan Science and Technology Agency (JST) (to ME) and a Grant-in-Aid for Scientific Research (B, 18H02363), the Ministry of Education, Culture, Sports, Science and Technology (to ME). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006;312: 549–60. 10.1016/j.yexcr.2005.11.012 [DOI] [PubMed] [Google Scholar]
- 2.Matsumoto K, Ema M. Roles of VEGF-A signalling in development, regeneration, and tumours. J Biochem. 2014;156: 1–10. 10.1093/jb/mvu031 [DOI] [PubMed] [Google Scholar]
- 3.Deng Y, Zhang X, Simons M. Molecular controls of lymphatic VEGFR3 signaling. Arterioscler Thromb Vasc Biol. 2015;35: 421–9. 10.1161/ATVBAHA.114.304881 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9: 669–76. 10.1038/nm0603-669 [DOI] [PubMed] [Google Scholar]
- 5.Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92: 3566–70. Available: http://www.ncbi.nlm.nih.gov/pubmed/7724599 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Alitalo K. The lymphatic vasculature in disease. Nat Med. 2011;17: 1371–80. 10.1038/nm.2545 [DOI] [PubMed] [Google Scholar]
- 7.Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454: 656–60. 10.1038/nature07083 [DOI] [PubMed] [Google Scholar]
- 8.Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011;437: 169–83. 10.1042/BJ20110301 [DOI] [PubMed] [Google Scholar]
- 9.Calvo C-F, Fontaine RH, Soueid J, Tammela T, Makinen T, Alfaro-Cervello C, et al. Vascular endothelial growth factor receptor 3 directly regulates murine neurogenesis. Genes Dev. 2011;25: 831–44. 10.1101/gad.615311 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Ishitobi H, Matsumoto K, Azami T, Itoh F, Itoh S, Takahashi S, et al. Flk1-GFP BAC Tg mice: an animal model for the study of blood vessel development. Exp Anim. 2010;59: 615–22. Available: http://www.ncbi.nlm.nih.gov/pubmed/21030789 [DOI] [PubMed] [Google Scholar]
- 11.Matsumoto K, Azami T, Otsu A, Takase H, Ishitobi H, Tanaka J, et al. Study of normal and pathological blood vessel morphogenesis in Flt1-tdsRed BAC Tg mice. Genesis. 2012;50: 561–71. 10.1002/dvg.22031 [DOI] [PubMed] [Google Scholar]
- 12.Ishitobi H, Wakamatsu A, Liu F, Azami T, Hamada M, Matsumoto K, et al. Molecular basis for Flk1 expression in hemato-cardiovascular progenitors in the mouse. Development. 2011;138: 5357–68. 10.1242/dev.065565 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Okabe K, Kobayashi S, Yamada T, Kurihara T, Tai-Nagara I, Miyamoto T, et al. Neurons limit angiogenesis by titrating VEGF in retina. Cell. 2014;159: 584–96. 10.1016/j.cell.2014.09.025 [DOI] [PubMed] [Google Scholar]
- 14.Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, Miyawaki A. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol. 2002;20: 87–90. 10.1038/nbt0102-87 [DOI] [PubMed] [Google Scholar]
- 15.Ema M, Takahashi S, Rossant J. Deletion of the selection cassette, but not cis-acting elements, in targeted Flk1-lacZ allele reveals Flk1 expression in multipotent mesodermal progenitors. Blood. 2006;107: 111–7. 10.1182/blood-2005-05-1970 [DOI] [PubMed] [Google Scholar]
- 16.Ema M, Yokomizo T, Wakamatsu A, Terunuma T, Yamamoto M, Takahashi S. Primitive erythropoiesis from mesodermal precursors expressing VE-cadherin, PECAM-1, Tie2, endoglin, and CD34 in the mouse embryo. Blood. 2006;108: 4018–24. 10.1182/blood-2006-03-012872 [DOI] [PubMed] [Google Scholar]
- 17.Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: An open-source platform for biological-image analysis. Nat Methods. 2012;9: 676–682. 10.1038/nmeth.2019 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Alishekevitz D, Gingis-Velitski S, Kaidar-Person O, Gutter-Kapon L, Scherer SD, Raviv Z, et al. Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3. Cell Rep. 2016;17: 1344–1356. 10.1016/j.celrep.2016.09.083 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Klotz L, Norman S, Vieira JM, Masters M, Rohling M, Dubé KN, et al. Cardiac lymphatics are heterogeneous in origin and respond to injury. Nature. 2015;522: 62–7. 10.1038/nature14483 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Zhong W, Gao X, Wang S, Han K, Ema M, Adams S, et al. Prox1-GFP/Flt1-DsRed transgenic mice: an animal model for simultaneous live imaging of angiogenesis and lymphangiogenesis. Angiogenesis. 2017;20: 581–598. 10.1007/s10456-017-9572-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science. 1998;282: 946–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/9794766 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All relevant data are within the paper and its Supporting Information files.